We use cookies for a better user experience. Read our Privacy Policy

I Agree

Gout Therapeutics Market

Gout Therapeutics Market (Drug Type: NSAIDS, Colchicine, Corticosteroids, Urate-lowering Drugs, and Biologics) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031

Gout Therapeutics Market Outlook 2031

  • The global gout therapeutics market was valued at US$ 2.2 Bn in 2021
  • The global market is projected to grow at a CAGR of 8.4% from 2022 to 2031
  • The global gout therapeutics market is anticipated to reach more than US$ 4.9 Bn by the end of 2031

Analysts’ Viewpoint on Gout Therapeutics Market Scenario

Gout is a metabolic disorder caused by an increase in uric acid levels in the body, which leads to the development of gouty arthritis. Gout treatment necessitates both pharmacological and non-pharmacological measures. Newer drugs that target different inflammatory mediators, enzymes, or transporters are in various stages of clinical development. Several drugs have moderate-to-high evidence of benefit for pain relief in patients with acute gout. NSAIDs, colchicine, and glucocorticoids have long been used as prophylaxis when starting urate-lowering therapy (ULT) and to treat the inflammation of acute gout attacks. All of these are considered first-line treatments for acute gout, and combination therapy can be used in severe cases. Gout is becoming more common and poses a significant health risk. Despite the fact that gout treatment has been known since long, there are still many challenges in gout management. Increased investment in research and development programs by key players is expected to drive the global gout therapeutics market during the forecast period.

Gout Therapeutics Market

Gout Therapeutics Market Introduction

Gout is an inflammatory arthritic condition caused by the deposition of monosodium crystals (MSU) into the distal joints and peripheral tissues. Gout is a common form of inflammatory arthritis that is quite painful. It usually affects one joint at a time (often the big toe joint). There are times when symptoms get worse, known as flares, and times when there are no symptoms, known as remission.

Gout is a common and complex form of arthritis that can affect anyone. It is characterized by sudden, severe attacks of pain, swelling, redness, and tenderness in one or more joints, most often in the big toe. It usually occurs earlier in men than women. It generally occurs after menopause in women. Men can be three times more likely than women to get it because they have higher levels of uric acid most of their lives. Women reach these uric acid levels after menopause.

Gout treatment exist; however, therapy should be tailored for each person. Treatment choices depend on kidney function, other health issues, personal preferences, and other factors. Patients could need medications to lower their elevated blood uric acid levels that predispose to gout. Over time, increased uric acid levels in the blood could lead to deposits of urate crystals in and around the joints. These crystals can attract white blood cells, leading to severe, painful gout attacks and chronic arthritis.

Request a sample to get extensive insights into the Gout Therapeutics Market

Increase in Incidence of Gout Propelling Global Gout Therapeutics Market

Gout is the most common type of inflammatory arthropathy. According to several studies, its prevalence and incidence have increased in the last few decades. Hyperuricemia, genetic factors, dietary factors, alcohol consumption, metabolic syndrome, hypertension, obesity, diuretic use, and chronic renal disease are the risk factors for the development of gout.

Several studies have shown that gout management in primary care is suboptimal, which could contribute to rise in prevalence of clinically significant symptomatic gout. Obesity, diabetes, and hypertension were found to be common in gout patients in the U.K. and Germany. Age is also a risk factor; hence, population aging is likely to increase the incidence of gout. Complex cases of gout, particularly secondary gout, are becoming more common in hospital practice, with the rising prevalence of advanced chronic kidney disease and usage of diuretics and nephrotoxic drugs potentially driving the global gout therapeutics market size.

Gout incidence and prevalence increases with age, with prevalence reaching 11% to 13% and incidence reaching 0.4% in people over the age of 80. Gout is more common in racial minorities in the U.S., New Zealand Mori, Han Chinese, and some ethnic groups in Asia Pacific.

Rise in Need to Reduce Inflammation and Pain in Joints Augmenting Nonsteroidal Anti‐inflammatory Drugs (NSAIDs) Segment

In terms of drug type, the nonsteroidal anti‐inflammatory drugs (NSAIDs) segment accounted for the largest gout therapeutic market share in 2021. NSAIDs are aspirin-like medications that can reduce inflammation and pain in joints and other tissues. NSAIDs, such as indomethacin (Indocin) and naproxen (Naprosyn), have become the treatment of choice for the majority of acute gout attacks. There is no evidence that one NSAID is superior to another. High doses of short-acting NSAIDs provide the quickest symptom relief. These medications could cause stomach upset, ulcers, or diarrhea; however, most people tolerate them well when used for a short period of time.

Urate-lowering drugs are utilized for the symptomatic treatment of gout arthritis, as a first line of therapy or in combination therapy. According to estimates, more than 2 million people in the U.S. take medication to decrease serum uric acid levels. Moreover, higher penetration of urate-lowering drugs compared to biologics into the gout therapeutics market for the treatment of people suffering from chronic or acute gout diseases propels the antihyperuricemic agents (urate-lowering drugs) segment.

Request a custom report on Gout Therapeutics Market

Increase in Geriatric Population with Moderate to Severe Gout Arthritis Propelling Hospital Pharmacies Segment

Based on distribution channel, the hospital pharmacies segment is projected to account for a dominant share of the global gout therapeutic market in 2021. The segment is anticipated to grow considerably from 2022 to 2031. Hospital pharmacies is expected to be the second-leading segment, in terms of market share, during the forecast period. The segment's large market share is attributed to the increase in geriatric population with moderate to severe gout arthritis requiring hospital pharmacy to purchase drugs.

The online pharmacies segment is likely to grow at a rapid pace during the forecast period. Increase in the number of online pharmacies and acceptance of several gout therapeutics as over-the-counter drugs in medical therapy to penetrate the pharmaceutical and the health care market are projected to augment the online pharmacies segment.

Regional Outlook of Global Gout Therapeutics Market

North America accounted for the largest share of the global gout therapeutics market in 2021. The region is projected to be a highly lucrative market during the forecast period, with high market attractiveness index. Increasing incidence of gout and rising burden of comorbidities in the U.S. are likely to propel the market in the region during the forecast period. Gout is the most common inflammatory arthritis in the country. Several studies have shown an increase in prevalence in the last few decades. There are more than nine million gout patients, and nearly a third of those patients are treated with oral urate-lowering therapies in the past 20 years. The number of people living with gout-related disability has risen steeply in the past few years.

The market in Asia Pacific is expected to grow at a rapid pace from 2022 to 2031. The incidence and prevalence of gout have been steadily increasing in the region, which has resulted in increased research & development activities in gout diagnosis and gout treatment.

Analysis of Key Players in Global Gout Therapeutics Market

The global gout therapeutics market is consolidated, with the presence of small number of leading players. Expansion of product portfolio and mergers & acquisitions are the key strategies adopted by the leading players in the global gout therapeutics market. Takeda Pharmaceutical Company Limited, Teijin Pharma Limited, Novartis AG, Mylan N.V., MERCK & Co. Inc., Iroko Pharmaceutical LLC, Hikma Pharmaceuticals plc, Horizon Therapeutics plc, and Teva Pharmaceutical Industries Ltd. are the prominent players operating in the global gout therapeutics market.

Key Developments in Global Gout Therapeutics Market

  • In August 2022, Synlogic, Inc., a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases using its proprietary synthetic biology approach, announced the development of a new drug candidate for the treatment of gout in collaboration with Ginkgo Bioworks, a leading horizontal platform for cell programming
  • In July 2022, Horizon Therapeutics' supplemental Biologics License Application (sBLA) for the Krystexxa (pegloticase) injection, given in conjunction with methotrexate, to help uncontrolled gout patients achieve a complete response to treatment received approval from the U.S. Food and Drug Administration (FDA).
  • In June 2021, Arrowhead Pharmaceuticals, Inc. and Horizon Therapeutics plc announced a global collaboration and license agreement for ARO-XDH, a previously unknown discovery-stage investigational RNA interference (RNAi) therapeutic being developed by Arrowhead as a potential treatment for uncontrolled gout

Each of these players has been profiled in the gout therapeutics market report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.

Global Gout Therapeutics Market Snapshot

Attribute

Detail

Market Size Value in 2021

US$ 2.2 Bn

Market Forecast Value in 2031

More than US$ 4.9 Bn

Growth Rate

(CAGR)

8.4%

Forecast Period

2022–2031

Historical Data Available for

2017–2020

Quantitative Units

US$ Bn for Value

Market Analysis

It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis.

Competition Landscape

  • Market share analysis by company (2021)
  • Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials

Format

Electronic (PDF) + Excel

Market Segmentation

  • Drug Type
    • NSAIDS
    • Colchicine
    • Corticosteroids
    • Urate-lowering Drugs
    • Biologics
  • Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies

Regions Covered

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa

Countries Covered

  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • China
  • India
  • Japan
  • Australia & New Zealand
  • Brazil
  • Mexico
  • South Africa
  • GCC Countries

Companies Profiled

  • AstraZeneca
  • Hikma Pharmaceuticals plc
  • Horizon Pharma plc.
  • Iroko Pharmaceuticals, LLC
  • Merck & CO., Inc.
  • Mylan N.V.
  • Novartis AG
  • Takeda Pharmaceutical Company Limited,
  • Teijin Pharma Limited.
  • Teva Pharmaceutical Industries Ltd.

Customization Scope

Available upon request

Pricing

Available upon request

Gout Therapeutics Market

Interested in this report?
Get a FREE Brochure now!

Get Free Brochure

*Get Brochure Report (PDF) sent to your email within minutes

Frequently Asked Questions

How big was the global gout therapeutics market in 2021?

The global gout therapeutics market was valued at US$ 2.2 Bn in 2021.

How big will be the global gout therapeutics market in 2031?

The global market is projected to reach more than US$ 4.9 Bn by 2031.

What will be the CAGR of the global gout therapeutics market during the forecast period (2022–2031)?

The global gout therapeutics market is anticipated to grow at a CAGR of 8.4% from 2022 to 2031.

Which are the prominent trends that affect market growth?

Increase in incidence of gout and the link between alcohol consumption and gout.

Which region will account for major share of the global market during the forecast period?

North America is expected to account for major share of the global gout therapeutics market during the forecast period.

Who are the prominent players in the global gout therapeutics market?

GlaxoSmithKline plc, Savient Pharmaceuticals, Takeda Pharmaceutical Company Ltd., Novartis AG, AstraZeneca plc, Merck & Co. Inc., Teijin Pharma Ltd., and Regeneron Pharmaceuticals.

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Gout Therapeutics Market

4. Market Overview

    4.1. Introduction

        4.1.1. Definition

        4.1.2. Industry Evolution / Developments

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. Global Gout Therapeutics Market Analysis and Forecast, 2017–2031

5. Key Insights

    5.1. Global Skincare Drug Types Market

    5.2. Key Industry Events (mergers, acquisitions, collaborations, approvals, etc.)

    5.3. COVID-19 Impact Analysis

6. Global Gout Therapeutics Market Analysis and Forecast, by Drug Type

    6.1. Introduction & Definition

    6.2. Key Findings / Developments

    6.3. Market Value Forecast, by Drug Type, 2017–2031

        6.3.1. NSAIDS

        6.3.2. Colchicine

        6.3.3. Corticosteroids

        6.3.4. Urate-lowering Drugs

        6.3.5. Biologics

    6.4. Market Attractiveness Analysis, by Drug Type

7. Global Gout Therapeutics Market Analysis and Forecast, by Distribution Channel

    7.1. Introduction & Definition

    7.2. Key Findings / Developments

    7.3. Market Value Forecast, by Distribution Channel, 2017–2031

        7.3.1. Hospital Pharmacies

        7.3.2. Retail Pharmacies

        7.3.3. Online Pharmacies

    7.4. Market Attractiveness Analysis, by Distribution Channel

8. Global Gout Therapeutics Market Analysis and Forecast, by Region

    8.1. Key Findings

    8.2. Market Value Forecast, by Region

        8.2.1. North America

        8.2.2. Europe

        8.2.3. Asia Pacific

        8.2.4. Latin America

        8.2.5. Middle East & Africa

    8.3. Market Attractiveness Analysis, by Region

9. North America Gout Therapeutics Market Analysis and Forecast

    9.1. Introduction

        9.1.1. Key Findings

    9.2. Market Value Forecast, by Drug Type, 2017–2031

        9.2.1. NSAIDS

        9.2.2. Colchicine

        9.2.3. Corticosteroids

        9.2.4. Urate-lowering Drugs

        9.2.5. Biologics

    9.3. Market Value Forecast, by Distribution Channel, 2017–2031

        9.3.1. Hospital Pharmacies

        9.3.2. Retail Pharmacies

        9.3.3. Online Pharmacies

    9.4. Market Value Forecast, by Country, 2017–2031

        9.4.1. U.S.

        9.4.2. Canada

    9.5. Market Attractiveness Analysis

        9.5.1. By Drug Type

        9.5.2. By Distribution Channel

        9.5.3. By Country

10. Europe Gout Therapeutics Market Analysis and Forecast

    10.1. Introduction

        10.1.1. Key Findings

    10.2. Market Value Forecast, by Drug Type, 2017–2031

        10.2.1. NSAIDS

        10.2.2. Colchicine

        10.2.3. Corticosteroids

        10.2.4. Urate-lowering Drugs

        10.2.5. Biologics

    10.3. Market Value Forecast, by Distribution Channel, 2017–2031

        10.3.1. Hospital Pharmacies

        10.3.2. Retail Pharmacies

        10.3.3. Online Pharmacies

    10.4. Market Value Forecast, by Country/Sub-region, 2017–2031

        10.4.1. Germany

        10.4.2. U.K.

        10.4.3. France

        10.4.4. Italy

        10.4.5. Spain

        10.4.6. Rest of Europe

    10.5. Market Attractiveness Analysis

        10.5.1. By Drug Type

        10.5.2. By Distribution Channel

        10.5.3. By Country/Sub-region

11. Asia Pacific Gout Therapeutics Market Analysis and Forecast

    11.1. Introduction

        11.1.1. Key Findings

    11.2. Market Value Forecast, by Drug Type, 2017–2031

        11.2.1. NSAIDS

        11.2.2. Colchicine

        11.2.3. Corticosteroids

        11.2.4. Urate-lowering Drugs

        11.2.5. Biologics

    11.3. Market Value Forecast, by Distribution Channel, 2017–2031

        11.3.1. Hospital Pharmacies

        11.3.2. Retail Pharmacies

        11.3.3. Online Pharmacies

    11.4. Market Value Forecast, by Country/Sub-region, 2017–2031

        11.4.1. China

        11.4.2. Japan

        11.4.3. India

        11.4.4. Australia & New Zealand

        11.4.5. Rest of Asia Pacific

    11.5. Market Attractiveness Analysis

        11.5.1. By Drug Type

        11.5.2. By Distribution Channel

        11.5.3. By Country/Sub-region

12. Latin America Gout Therapeutics Market Analysis and Forecast

    12.1. Introduction

        12.1.1. Key Findings

    12.2. Market Value Forecast, by Drug Type, 2017–2031

        12.2.1. NSAIDS

        12.2.2. Colchicine

        12.2.3. Corticosteroids

        12.2.4. Urate-lowering Drugs

        12.2.5. Biologics

    12.3. Market Value Forecast, by Distribution Channel, 2017–2031

        12.3.1. Hospital Pharmacies

        12.3.2. Retail Pharmacies

        12.3.3. Online Pharmacies

    12.4. Market Value Forecast, by Country/Sub-region, 2017–2031

        12.4.1. Brazil

        12.4.2. Mexico

        12.4.3. Rest of Latin America

    12.5. Market Attractiveness Analysis

        12.5.1. By Drug Type

        12.5.2. By Distribution Channel

        12.5.3. By Country/Sub-region

13. Middle East & Africa Gout Therapeutics Market Analysis and Forecast

    13.1. Introduction

        13.1.1. Key Findings

    13.2. Market Value Forecast, by Drug Type, 2017–2031

        13.2.1. NSAIDS

        13.2.2. Colchicine

        13.2.3. Corticosteroids

        13.2.4. Urate-lowering Drugs

        13.2.5. Biologics

    13.3. Market Value Forecast, by Distribution Channel, 2017–2031

        13.3.1. Hospital Pharmacies

        13.3.2. Retail Pharmacies

        13.3.3. Online Pharmacies

    13.4. Market Value Forecast, by Country/Sub-region, 2017–2031

        13.4.1. GCC Countries

        13.4.2. South Africa

        13.4.3. Rest of Middle East & Africa

    13.5. Market Attractiveness Analysis

        13.5.1. By Drug Type

        13.5.2. By Distribution Channel

        13.5.3. By Country/Sub-region

14. Competition Landscape

    14.1. Market Player - Competitive Matrix (by tier and size of companies)

    14.2. Market Share Analysis, by Company, 2021

        14.2.1. Takeda Pharmaceutical Company Limited

            14.2.1.1. Company Overview (HQ, Business Segments, Employee Strengths)

            14.2.1.2. Product Portfolio

            14.2.1.3. SWOT Analysis

            14.2.1.4. Strategic Overview

            14.2.1.5. Financial Overview

        14.2.2. Teijin Pharma Limited

            14.2.2.1. Company Overview (HQ, Business Segments, Employee Strengths)

            14.2.2.2. Product Portfolio

            14.2.2.3. SWOT Analysis

            14.2.2.4. Strategic Overview

            14.2.2.5. Financial Overview

        14.2.3. Novartis AG

            14.2.3.1. Company Overview (HQ, Business Segments, Employee Strengths)

            14.2.3.2. Product Portfolio

            14.2.3.3. SWOT Analysis

            14.2.3.4. Strategic Overview

            14.2.3.5. Financial Overview

        14.2.4. Mylan N.V.

            14.2.4.1. Company Overview (HQ, Business Segments, Employee Strengths)

            14.2.4.2. Product Portfolio

            14.2.4.3. SWOT Analysis

            14.2.4.4. Strategic Overview

            14.2.4.5. Financial Overview

        14.2.5. Horizon Pharma plc

            14.2.5.1. Company Overview (HQ, Business Segments, Employee Strengths)

            14.2.5.2. Product Portfolio

            14.2.5.3. SWOT Analysis

            14.2.5.4. Strategic Overview

            14.2.5.5. Financial Overview

        14.2.6. Teva Pharmaceutical Industries Ltd.

            14.2.6.1. Company Overview (HQ, Business Segments, Employee Strengths)

            14.2.6.2. Product Portfolio

            14.2.6.3. SWOT Analysis

            14.2.6.4. Strategic Overview

            14.2.6.5. Financial Overview

        14.2.7. Hikma Pharmaceuticals plc

            14.2.7.1. Company Overview (HQ, Business Segments, Employee Strengths)

            14.2.7.2. Product Portfolio

            14.2.7.3. SWOT Analysis

            14.2.7.4. Strategic Overview

            14.2.7.5. Financial Overview

        14.2.8. Iroko Pharmaceuticals, LLC

            14.2.8.1. Company Overview (HQ, Business Segments, Employee Strengths)

            14.2.8.2. Product Portfolio

            14.2.8.3. SWOT Analysis

            14.2.8.4. Strategic Overview

            14.2.8.5. Financial Overview

        14.2.9. MERCK & CO., Inc.

            14.2.9.1. Company Overview (HQ, Business Segments, Employee Strengths)

            14.2.9.2. Product Portfolio

            14.2.9.3. SWOT Analysis

            14.2.9.4. Strategic Overview

            14.2.9.5. Financial Overview

List of Tables

Table 01: Global Gout Therapeutics Market Size (US$ Mn) Forecast, by Drug Type, 2017–2031

Table 02: Global Gout Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 03: Global Gout Therapeutics Market Size (US$ Mn) Forecast, by Region, 2017–2031

Table 04: North America Gout Therapeutics Market Size (US$ Mn) Forecast, by Country, 2017–2031

Table 05: North America Gout Therapeutics Market Size (US$ Mn) Forecast, by Drug Type, 2017–2031

Table 06: North America Gout Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 07: Europe Gout Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 08: Europe Gout Therapeutics Market Size (US$ Mn) Forecast, by Drug Type, 2017–2031

Table 09: Europe Gout Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 10: Asia Pacific Gout Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 11: Asia Pacific Gout Therapeutics Market Size (US$ Mn) Forecast, by Drug Type, 2017–2031

Table 12: Asia Pacific Gout Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 13: Latin America Gout Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 14: Latin America Gout Therapeutics Market Size (US$ Mn) Forecast, by Drug Type, 2017–2031

Table 15: Latin America Gout Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 16: Middle East & Africa Gout Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 17: Middle East & Africa Gout Therapeutics Market Size (US$ Mn) Forecast, by Drug Type, 2017–2031

Table 18: Middle East & Africa Gout Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031

List of Figures

Figure 01: Global Gout Therapeutics Market Size (US$ Mn) and Distribution (%), by Region, 2017 and 2031

Figure 02: Global Gout Therapeutics Market Revenue (US$ Mn), by Drug Type, 2021

Figure 03: Global Gout Therapeutics Market Value Share, by Drug Type, 2021

Figure 04: Global Gout Therapeutics Market Value Share, by Distribution Channel, 2021

Figure 05: Global Gout Therapeutics Market Value Share, by Region, 2021

Figure 06: Global Gout Therapeutics Market Value (US$ Mn) Forecast, 2017–2031

Figure 07: Global Gout Therapeutics Market Value Share Analysis, by Drug Type, 2017 and 2031

Figure 08: Global Gout Therapeutics Market Attractiveness Analysis, by Drug Type, 2022-2031

Figure 09: Global Gout Therapeutics Market Value Share Analysis, by Distribution Channel, 2017 and 2031

Figure 10: Global Gout Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2022-2031

Figure 11: Global Gout Therapeutics Market Value Share Analysis, by Region, 2017 and 2031

Figure 12: Global Gout Therapeutics Market Attractiveness Analysis, by Region, 2022-2031

Figure 13: North America Gout Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031

Figure 14: North America Gout Therapeutics Market Attractiveness Analysis, by Country, 2017–2031

Figure 15: North America Gout Therapeutics Market Value Share Analysis, by Country, 2017 and 2031

Figure 16: North America Gout Therapeutics Market Value Share Analysis, by Drug Type, 2017 and 2031

Figure 17: North America Gout Therapeutics Market Value Share Analysis, by Distribution Channel, 2017 and 2031

Figure 18: North America Gout Therapeutics Market Attractiveness Analysis, by Drug Type, 2022–2031

Figure 19: North America Gout Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2022–2031

Figure 20: Europe Gout Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031

Figure 21: Europe Gout Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2017–2031

Figure 22: Europe Gout Therapeutics Market Value Share Analysis, by Country/Sub-region, 2017 and 2031

Figure 23: Europe Gout Therapeutics Market Value Share Analysis, by Drug Type, 2017 and 2031

Figure 24: Europe Gout Therapeutics Market Value Share Analysis, by Distribution Channel, 2017 and 2031

Figure 25: Europe Gout Therapeutics Market Attractiveness Analysis, by Drug Type, 2022–2031

Figure 26: Europe Gout Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2022–2031

Figure 27: Asia Pacific Gout Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031

Figure 28: Asia Pacific Gout Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2017–2031

Figure 29: Asia Pacific Gout Therapeutics Market Value Share Analysis, by Country/Sub-region, 2017 and 2031

Figure 30: Asia Pacific Gout Therapeutics Market Value Share Analysis, by Drug Type, 2017 and 2031

Figure 31: Asia Pacific Gout Therapeutics Market Value Share Analysis, by Distribution Channel, 2017 and 2031

Figure 32: Asia Pacific Gout Therapeutics Market Attractiveness Analysis, by Drug Type, 2022–2031

Figure 33: Asia Pacific Gout Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2022–2031

Figure 34: Latin America Gout Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031

Figure 35: Latin America Gout Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2017–2031

Figure 36: Latin America Gout Therapeutics Market Value Share Analysis, by Country/Sub-region, 2017 and 2031

Figure 37: Latin America Gout Therapeutics Market Value Share Analysis, by Drug Type, 2017 and 2031

Figure 38: Latin America Gout Therapeutics Market Value Share Analysis, by Distribution Channel, 2017 and 2031

Figure 39: Latin America Gout Therapeutics Market Attractiveness Analysis, by Drug Type, 2022–2031

Figure 40: Latin America Gout Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2022–2031

Figure 41: Middle East & Africa Gout Therapeutics Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031

Figure 42: Middle East & Africa Gout Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2017–2031

Figure 43: Middle East & Africa Gout Therapeutics Market Value Share Analysis, by Country/Sub-region, 2017 and 2031

Figure 44: Middle East & Africa Gout Therapeutics Market Value Share Analysis, by Drug Type, 2017 and 2031

Figure 45: Middle East & Africa Gout Therapeutics Market Value Share Analysis, by Distribution Channel, 2017 and 2031

Figure 46: Middle East & Africa Gout Therapeutics Market Attractiveness Analysis, by Drug Type, 2022–2031

Figure 47: Middle East & Africa Gout Therapeutics Market Attractiveness Analysis, by Application, 2022–2031

Figure 48: Middle East & Africa Gout Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2022–2031

Transparency Market Research Plus
  • We offer 100% free customisation with our Enterprise License!!
  • Get a free copy if the report you purchased is updated within 90 days
  • Regardless from where you have purchased the report, you can request an updated version of the report from us.

Complete the form below and we'll get back to you shortly.

582

Your personal details are safe with us. Privacy Policy*

Copyright © Transparency Market Research, Inc. All Rights reserved